Dr.ย Jieย Wang
MD, PhD
Chair, Medical Oncology Division & Thoracic Medical Oncologist
corporate_fareNational Cancer Center / Cancer Hospital, CAMS, Beijing
Jie Wang
MD, PhD
Prof. Jie Wang is a senior thoracic medical oncologist and one of China's leading specialists in lung cancer treatment, precision oncology and translational research. She is Chair of the Medical Oncology Division at the National Cancer Center and Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS) in Beijing, and a tenured professor at Peking Union Medical College.
With more than three decades of clinical experience, Prof. Wang focuses on the multidisciplinary management of lung cancer and other thoracic malignancies, including complex and advanced cases that need biomarker-guided targeted therapy, immunotherapy and carefully planned combination treatment. She is recognised for her work in molecular subtyping and personalised treatment selection in non-small cell and small-cell lung cancer. Her research has helped establish non-invasive molecular profiling using circulating tumour DNA as an important tool for treatment selection and disease monitoring. She has published more than 150 articles as a corresponding author in journals including The Lancet Oncology, Cancer Cell, The Lancet Respiratory Medicine and the Journal of Clinical Oncology, and has led or co-led major phase III lung cancer trials. In 2023 she received the IASLC Heine H. Hansen Lectureship Award.
CancerFax can coordinate medical-report review and second-opinion support for international patients seeking an opinion from Prof. Wang, subject to hospital availability and case acceptance.
Why Consider Prof. Jie Wang?
Prof. Wang combines more than 30 years of thoracic oncology practice with internationally recognised research in lung cancer precision medicine.
Areas of Specialisation
Precision-guided systemic treatment for thoracic cancers
Prof. Wang uses molecular testing and tumour biomarkers to guide individualised treatment for lung cancer and other thoracic malignancies.
Precision Oncology & Targeted Therapy
Biomarker-guided systemic treatment for molecularly defined lung cancers.
- arrow_rightEGFR-mutated lung cancer, including treatment after progression
- arrow_rightALK, ROS1, RET, MET, BRAF and KRAS-altered lung cancer
- arrow_rightEvaluation of resistance after EGFR tyrosine kinase inhibitor therapy
- arrow_rightTreatment selection based on pathology and biomarker results
- arrow_rightCirculating tumour DNA (ctDNA) for treatment selection and monitoring
Immunotherapy for Thoracic Cancers
Immune-checkpoint and biomarker-guided immunotherapy strategies.
- arrow_rightPD-1 and PD-L1 inhibitors for suitable patients
- arrow_rightChemotherapy combined with PD-1-based immunotherapy
- arrow_rightctDNA-informed selection of patients likely to benefit
Procedures & Clinical Services
Systemic treatment, molecular diagnostics and expert review
Prof. Wang's clinical services focus on systemic cancer treatment and precision-guided care for thoracic malignancies.
Systemic Cancer Treatment
Medical OncologyTreatment planning and administration of systemic therapy for thoracic cancers.
Targeted Therapy
Targeted TherapyMolecularly guided targeted treatment for actionable alterations.
Molecular Diagnostics & Staging
DiagnosisBiomarker testing and molecular profiling to guide treatment decisions.
Second Opinion Consultations
Second OpinionIndependent expert review of pathology, imaging and treatment history for thoracic cancers.
Research & Publications
Lung cancer precision medicine and phase III trial leadership
Prof. Wang's research focuses on precision treatment of lung cancer, molecular profiling and liquid biopsy, targeted-therapy resistance and immunotherapy response prediction.
Prof. Wang's active research and trial work means eligible patients may be evaluated for newer treatment options. A more detailed publication list can be requested through CancerFax.
Education & Training
Prof. Wang completed her medical, pathology and doctoral training in China, followed by international academic experience at MD Anderson Cancer Center in the United States.
Clinical Experience
Prof. Wang has more than 30 years of clinical and academic experience in thoracic oncology, including senior leadership roles at leading Chinese cancer centres and a visiting academic post at MD Anderson Cancer Center.
Languages & International
Prof. Wang consults in the following language.
CancerFax can coordinate professional medical interpreter support so language is not a barrier for international patients.
English-language consultation support can be confirmed during appointment coordination. CancerFax can arrange professional medical interpreter support for international patients.
How CancerFax Helps You Access Dr. Jie Wang
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Jie Wang's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Jie Wang's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Jie Wang before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Jie Wang's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Jie Wang's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Jie Wang's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Jie Wang
Yes. Prof. Wang is a senior thoracic medical oncologist with more than 30 years of experience. Her work focuses primarily on lung cancer, including precision treatment, targeted therapy, immunotherapy and clinical research at the National Cancer Center in Beijing.
Yes. EGFR-mutated and ALK-positive lung cancer, molecular testing and resistance after targeted therapy are central to her clinical and research work. She also evaluates treatment options after progression on earlier targeted therapy.
International patients may request a second opinion or appointment review through CancerFax, subject to the hospital's acceptance process and Prof. Wang's availability. Medical records should normally include the pathology report, imaging reports, treatment summary and molecular-testing results.
Submit your medical reports through CancerFax using the 'Send Your Reports' option. The CancerFax team reviews the documents, prepares the case for submission, and coordinates the next steps with the hospital, subject to availability.
Yes. In addition to lung cancer, her clinical experience includes thymic tumours and pleural mesothelioma, with a focus on standardised, individualised and multidisciplinary care.
Yes. She has led and co-led major lung cancer studies, including phase III trials such as CHOICE-01, CAPSTONE-1 and RATIONALE-307. Eligible patients may be evaluated for newer treatment or trial options through CancerFax-coordinated review, subject to the institution's processes.
Connect with Jie Wang Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.